NAFLD, NASH and liver cancer

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 11, 2013, Pages 656-665

  Michelotti, Gregory A ^a   Machado, Mariana V ^a   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 106B; MICRORNA 122; MICRORNA 195; MICRORNA 21; MICRORNA 216A; MICRORNA 217; MICRORNA 29A; MICRORNA 29C; MICRORNA 34A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

BILE DUCT CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARBON METABOLISM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; GENE; GENE INTERACTION; GENE TARGETING; GENETIC RISK; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NF KAPPAB GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PTEN GENE; REVIEW; RNA GENE; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; LIVER NEOPLASMS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 84887321419     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.183     Document Type: Review

References (115)

1. Lazo, M. et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Epidemiol. 178, 38-45 (2013).
2. Clark, J. M., Brancati, F. L. & Diehl, A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98, 960-967 (2003).
3. Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113-121 (2005).
4. McCullough, A. J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8, 521-533 (2004).
5. Holmberg, S. D., Spradling, P. R., Moorman, A. C. & Denniston, M. M. Hepatitis C in the United States. N. Engl. J. Med. 368, 1859-1861 (2013).
6. Yasui, K. et al. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol. Res. 42, 767-773 (2012).
7. Sorensen, H. T. et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J. Clin. Gastroenterol. 36, 356-359 (2003).
8. Yang, J. D. et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clinic Proc. 87, 9-16 (2012).
9. Hucke, F., Sieghart, W., Schöniger-Hekele, M., Peck-Radosavljevic, M. & Müller, C. Clinical characteristics of patients with hepatocellular carcinoma in Austria-is there a need for a structured screening program? Wien. Klin. Wochenschr. 123, 542-551 (2011).
10. Ertle, J. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128, 2436-2443 (2011).
11. Malik, S. M., Gupte, P. A., de Vera, M. E. & Ahmad, J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7, 800-806 (2009).
12. Kawada, N. et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol. 44, 1190-1194 (2009).
13. Tokushige, K., Hashimoto, E., Horie, Y., Taniai, M. & Higuchi, S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J. Gastroenterol. 46, 1230-1237 (2011).
14. Marrero, J. A. et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36, 1349-1354 (2002).
15. Lee, S. S. et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 13, 335 (2013).
16. Ohata, K. et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97, 3036-3043 (2003).
17. Pekow, J. R. et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C?related cirrhosis. Cancer 109, 2490-2496 (2007).
18. Tanaka, A. et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J. Gastroenterol. 13, 5180-5187 (2007).
19. Saini, H. K., Elimban, V., Ozcelikay, A. T. & Dhalla, N. S. Mechanisms of cardiodepression by an Na+?H+ exchange inhibitor methyl?N?isobutyl amiloride (MIA) on the heart: lack of beneficial effects in ischemia-reperfusion injury. Can. J. Physiol. Pharmacol. 85, 67-78 (2007).
20. Yu, M. W. et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J. Clin. Oncology 26, 5576-5582 (2008).
21. Machado, M. V., Oliveira, A. G. & Cortez-Pinto, H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 26, 1361-1367 (2011).
22. Kawamura, Y. et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am. J. Gastroenterol. 107, 253-261 (2012).
23. Hashimoto, E. et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 44 (Suppl. 19), 89-95 (2009).
24. White, D. L., Kanwal, F. & El-Serag, H. B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10, 1342-1359 (2012).
25. Guzman, G. et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch. Pathol. Lab. Med. 132, 1761-1766 (2008).
26. Paradis, V. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49, 851-859 (2009).
27. Arase, Y. et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol. Res. 42, 264-272 (2012).
28. Bhala, N. et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54, 1208-1216 (2011).
29. Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972-1978 (2010).
30. Sanyal, A. J. et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682-689 (2006).
31. Lazo, M. et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Epidemiol. 178, 38-45 (2013).
32. Clark, J. M., Brancati, F. L. & Diehl, A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98, 960-967 (2003).
33. Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113-121 (2005).
34. McCullough, A. J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8, 521-533 (2004).
35. Holmberg, S. D., Spradling, P. R., Moorman, A. C. & Denniston, M. M. Hepatitis C in the United States. N. Engl. J. Med. 368, 1859-1861 (2013).
36. Yasui, K. et al. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol. Res. 42, 767-773 (2012).
37. Sorensen, H. T. et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J. Clin. Gastroenterol. 36, 356-359 (2003).
38. Yang, J. D. et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clinic Proc. 87, 9-16 (2012).
39. Hucke, F., Sieghart, W., Schöniger-Hekele, M., Peck-Radosavljevic, M. & Müller, C. Clinical characteristics of patients with hepatocellular carcinoma in Austria-is there a need for a structured screening program? Wien. Klin. Wochenschr. 123, 542-551 (2011).
40. Ertle, J. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128, 2436-2443 (2011).
41. Malik, S. M., Gupte, P. A., de Vera, M. E. & Ahmad, J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7, 800-806 (2009).
42. Kawada, N. et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol. 44, 1190-1194 (2009).
43. Tokushige, K., Hashimoto, E., Horie, Y., Taniai, M. & Higuchi, S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J. Gastroenterol. 46, 1230-1237 (2011).
44. Marrero, J. A. et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36, 1349-1354 (2002).
45. Lee, S. S. et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 13, 335 (2013).
46. Ohata, K. et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97, 3036-3043 (2003).
47. Pekow, J. R. et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C?related cirrhosis. Cancer 109, 2490-2496 (2007).
48. Tanaka, A. et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J. Gastroenterol. 13, 5180-5187 (2007).
49. Saini, H. K., Elimban, V., Ozcelikay, A. T. & Dhalla, N. S. Mechanisms of cardiodepression by an Na+?H+ exchange inhibitor methyl?N?isobutyl amiloride (MIA) on the heart: lack of beneficial effects in ischemia-reperfusion injury. Can. J. Physiol. Pharmacol. 85, 67-78 (2007).
50. Yu, M. W. et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J. Clin. Oncology 26, 5576-5582 (2008).
51. Machado, M. V., Oliveira, A. G. & Cortez-Pinto, H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 26, 1361-1367 (2011).
52. Kawamura, Y. et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am. J. Gastroenterol. 107, 253-261 (2012).
53. Hashimoto, E. et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 44 (Suppl. 19), 89-95 (2009).
54. White, D. L., Kanwal, F. & El-Serag, H. B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10, 1342-1359 (2012).
55. Guzman, G. et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch. Pathol. Lab. Med. 132, 1761-1766 (2008).
56. Paradis, V. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49, 851-859 (2009).
57. Arase, Y. et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol. Res. 42, 264-272 (2012).
58. Bhala, N. et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54, 1208-1216 (2011).
59. Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972-1978 (2010).
60. Sanyal, A. J. et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682-689 (2006).
61. Johnson, A. R. et al. Deletion of murine choline dehydrogenase results in diminished sperm motility. FASEB J. 24, 2752-2761 (2010).
62. Lu, S. C. et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl Acad. Sci. USA 98, 5560-5565 (2001).
63. Martinez-Chantar, M. L. et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16, 1292-1294 (2002).
64. Teng, Y. W., Mehedint, M. G., Garrow, T. A. & Zeisel, S. H. Deletion of betaine-homocysteine S?methyltransferase in mice perturbs choline and 1?carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J. Biol. Chem. 286, 36258-36267 (2011).
65. Lu, S. C. & Mato, J. M. S?adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515-1542 (2012).
66. Frau, M., Feo, F. & Pascale, R. M. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J. Hepatol. 59, 830-841 (2013).
67. Liu, Q. et al. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S'adenosylmethionine production. J. Biol Chem. 286, 17168-17180 (2011).
68. Avila, M. A. et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 33, 907-914 (2000).
69. Cai, J., Sun, W. M., Hwang, J. J., Stain, S. C. & Lu, S. C. Changes in S'adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 24, 1090-1097 (1996).
70. Yang, H. et al. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J. Clin. Invest. 123, 285-298 (2013).
71. Cano, A. et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology 54, 1975-1986 (2011).
72. Sánchez-Quiles, V. et al. Prohibitin?1 deficiency promotes inflammation and increases sensitivity to liver injury. J. Proteomics 75, 5783-5792 (2012).
73. Ko, K. S. et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology 52, 2096-2108 (2010).
74. Santamaria, E. et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S'adenosylmethionine. Proc. Natl Acad. Sci. USA 100, 3065-3070 (2003).
75. Liao, Y. J. et al. Characterization of a glycine N'methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer 124, 816-826 (2009).
76. Martinez-Chantar, M. L. et al. Loss of the glycine N'methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47, 1191-1199 (2008).
77. Martinez-Lopez, N. et al. Hepatoma cells from mice deficient in glycine N'methyltransferase have increased RAS signaling and activation of liver kinase B1. Gastroenterology 143, 787-798 (2012).
78. Huidobro, C. et al. A DNA methylation signature associated with the epigenetic repression of glycine N?methyltransferase in human hepatocellular carcinoma. J. Mol. Med. (Berl.) 91, 939-950 (2013).
79. Ceccarelli, S., Panera, N., Gnani, D. & Nobili, V. Dual role of microRNAs in NAFLD. Int. J. Mol. Sci. 14, 8437-8455 (2013).
80. Chang, J. et al. miR?122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT?1. RNA Biol. 1, 106-113 (2004).
81. Rottiers, V. & Naar, A. M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 13, 239-250 (2012).
82. Esau, C. et al. miR?122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
83. Tsai, W. C. et al. MicroRNA?122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884-2897 (2012).
84. Burchard, J. et al. microRNA?122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol. Syst. Biol. 6, 402 (2010).
85. Meng, F. et al. MicroRNA?21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007).
86. Bao, L. et al. MicroRNA?21 suppresses PTEN and hSulf?1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett. 337, 226-236 (2013).
87. Wei, J., Feng, L., Li, Z., Xu, G. & Fan, X. MicroRNA?21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed. Pharmacother. 67, 387-392 (2013).
88. Wang, C., Bian, Z., Wei, D. & Zhang, J. G. miR?29b regulates migration of human breast cancer cells. Mol. Cell. Biochem. 352, 197-207 (2011).
89. Tumaneng, K. et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR?29. Nat. Cell Biol. 14, 1322-1329 (2012).
90. Kong, G. et al. Upregulated microRNA?29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS ONE 6, e19518 (2011).
91. Yau, W. L. et al. Over-expression of miR?106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS ONE 8, e57882 (2013).
92. Poliseno, L. et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Science Signal. 3, ra29 (2010).
93. Petrocca, F., Vecchione, A. & Croce, C. M. Emerging role of miR?106b?25/miR?17?92 clusters in the control of transforming growth factor ? signaling. Cancer Res. 68, 8191-8194 (2008).
94. Cai, K., Wang, Y. & Bao, X. MiR?106b promotes cell proliferation via targeting RB in laryngeal carcinoma. J. Exp. Clin. Cancer Res. 30, 73 (2011).
95. Meng, F. et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J. Cell. Mol. Med. 16, 160-173 (2012).
96. Wu, K. et al. Hepatic transforming growth factor ? gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 56, 2255-2267 (2012).
97. Yang, H., Fang, F., Chang, R. & Yang, L. MicroRNA?140?5p suppresses tumor growth and metastasis by targeting transforming growth factor ? receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58, 205-217 (2013).
98. Ding, J. et al. Genome-wide screening revealed that miR?195 targets the TNF-?/NF-?B pathway by downregulating IKK? and TAB3 in hepatocellular carcinoma. Hepatology 58, 654-666 (2013).
99. Lee, J. et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA?34a inhibition. J. Biol Chem. 285, 12604-12611 (2010).
100. Castro, R. E. et al. miR?34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 58, 119-125 (2013).
101. Lee, J. S. et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 36, 1306-1311 (2004).
102. Coulouarn, C., Factor, V. M., Conner, E. A. & Thorgeirsson, S. S. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 32, 1434-1440 (2011).
103. Roskams, T. et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Pathol. 163, 1301-1311 (2003).
104. Yang, S. et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 39, 403-411 (2004).
105. Torbenson, M. et al. STAT?3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am. J. Pathol. 161, 155-161 (2002).
106. Richardson, M. M. et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 133, 80-90 (2007).
107. Fleig, S. V. et al. Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice. Lab. Invest. 87, 1227-1239 (2007).
108. Tolosa, L. et al. Steatotic liver: a suitable source for the isolation of hepatic progenitor cells. Liver Int. 31, 1231-1238 (2011).
109. Budhu, A. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897-907 (2008).
110. Qu, K. Z., Zhang, K., Li, H., Afdhal, N. H. & Albitar, M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 45, 355-360 (2011).
111. Yamamoto, Y. et al. MicroRNA?500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14, 529-538 (2009).
112. Murakami, Y. et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537-2545 (2006).
113. Schwarz, M. et al. Role of receptors in human and rodent hepatocarcinogenesis. Mutat. Res. 333, 69-79 (1995).
114. Unger, C. et al. Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells. Cell Death Diff. 5, 87-95 (1998).
115. Gonçalves, P. L. et al. Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espfrito Santo. Clinics (Sao Paulo) 68, 291-295 (2013).